Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician

J Cardiothorac Vasc Anesth. 2016 Jun;30(3):823-30. doi: 10.1053/j.jvca.2016.01.005. Epub 2016 Jan 7.
No abstract available

Keywords: activated charcoal; andexanet; apixaban; aripazine; atrial fibrillation; dabigatran; direct thrombin inhibitor; edoxaban; factor Xa; idarucizumab; novel oral anticoagulants; prothrombin complex concentrates; recombinant factor VIIa; rivaroxaban; vitamin K antagonists; warfarin.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Anticoagulants / pharmacology*
  • Arginine / analogs & derivatives
  • Arginine / pharmacology
  • Blood Coagulation Factors / pharmacology
  • Factor VIIa / pharmacology
  • Factor Xa / pharmacology
  • Factor Xa Inhibitors / pharmacology
  • Humans
  • Piperazines / pharmacology
  • Recombinant Proteins / pharmacology
  • Renal Dialysis

Substances

  • Antibodies, Monoclonal, Humanized
  • Anticoagulants
  • Blood Coagulation Factors
  • Factor Xa Inhibitors
  • PRT064445
  • Piperazines
  • Recombinant Proteins
  • prothrombin complex concentrates
  • Arginine
  • idarucizumab
  • Factor VIIa
  • Factor Xa
  • PER977